Skip to content

Cannabis and Seniors

Cannabis and Seniors

As more and more research comes out regarding the medical benefits of cannabis, it’s important to keep up with new research as it becomes available.  Here at Arfinn Med, we constantly review new studies and look at our own deidentified efficacy data to try to find any additional insights we can relay to our registered users. With that in mind, we took a closer look at research coming out of the University of Illinois and the University of Iowa regarding the medicinal benefit of cannabis on Seniors.

The research found “strong positive association” between the frequency of cannabis use by Seniors and self-reported improvements in pain, health-care utilization, and overall health-related quality of life. The researchers revealed they had “identified a strong positive association between higher frequency of cannabis use and improvement to HRQL and HCU [health-care utilization] scores.”

With many clinics seeing an increase in the amount of Seniors turning to medical cannabis, we wanted to identify some additional trends through querying our database of deidentified data for patient demographics 60 and above.

Similar to what this report indicated, we found that Seniors self-reported an average 3.7 resolution of symptoms which translates on our scale to just below a ‘significant resolution’ of symptoms. In addition to the overall efficacy, we found that chronic pain was the most frequently sited qualifying condition with both THC dominant and balanced ratios of THC and CBD being the most frequently used cannabis profiles.  Lastly, in terms of mode of consumption, tinctures were the preferred route.

If you are interested in learning more about the efficacy of medical cannabis and would like to add our electronic medical record (EMR), practice management, and telehealth platform to your practice, please schedule a quick demo by contacting info@arfinnmed.com or by clicking here!

Stories you may be interested in

Cannabis and Mental Health: Social Anxiety Disorder

Social anxiety may sound like something we all experience at times in life, and that is true. It is natural for a person to feel nervous or anxious in situations like being alone in a new place or going on a first date. But for those living with social anxiety disorder, those instances of anxiety…
Read More

Norfolk research company plans clinical trials using medical marijuana

Eighteen months after receiving a broad federal license for importing medical cannabis, a Norfolk research company is about to embark on a series of critical studies into a variety of medical and mental disorders, diseases and conditions. Sanyal Biotechnology is already considering proposals for research campuses and planning its first clinical trial for this summer.…
Read More

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More

Updated Arfinn Med Scheduler

As your practice begins to grow, it’s important that your booking system is able to keep up.  That’s why Arfinn Med has just released, in its newest update, the multi-view scheduling and booking platform.  This allows you and/or your staff the ability to customize appointment types, hours of availability, display name, and confirmation emails for…
Read More

The Lack of Clinical Trials in the Medical Marijuana Industry

As time goes on, medical marijuana is starting to break barriers in various states across the country. Out of the 50 states, 33 have approved a comprehensive medical marijuana program (NCSL). Currently, marijuana, medical or recreational, is illegal at the federal level, despite legalization in various states. Many medical professionals are interested in prescribing medical…
Read More

Dr. Sanjay Gupta on medical marijuana: We are in an age of wisdom, but also an age of foolishness

When we released “Weed” in 2013, few people had ever heard of cannabidiol, or CBD. Now, two-thirds of Americans are familiar with the compound, and 1 in 7 have tried it. Most of the country, 93%, are in favor of medical marijuana and hemp-derived CBD itself, which has less than 0.3% THC, has been legalized in every state.It’s…
Read More

Leave a Comment

You must be logged in to post a comment.